Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EP Studies Should Return To Basics, FDA Says; CRT Trial Endpoints Assessed

This article was originally published in The Gray Sheet

Executive Summary

CDRH Division of Cardiovascular Devices Director Bram Zuckerman is warning manufacturers of an over-reliance on surrogate endpoints that the agency has observed in electrophysiology device trials
Advertisement

Related Content

Circulatory Panel Warms To Cardiac Freezor Despite Missed Trial Targets
Circulatory Panel Warms To Cardiac Freezor Despite Missed Trial Targets
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Advertisement
UsernamePublicRestriction

Register

MT018429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel